This research demonstrates enhanced risk stratification in prostate cancer using liquid biopsies for biomarkers, suggesting advancements in precision oncology.
Key Points
The research aims to explore the role of circulating microRNAs in prostate cancer for early detection, prognosis, and treatment monitoring.
Examined the potential of liquid biopsies to detect circulating microRNAs in prostate cancer patients.
Correlated miRNA expression patterns with disease aggressiveness and treatment responses.
Investigated the predictive value of baseline miRNA levels for chemotherapy outcomes.
Circulating microRNAs can serve as non-invasive biomarkers for early prostate cancer detection.
Distinct miRNA profiles correlate with tumor aggressiveness and treatment responses.
Integration of multi-miRNA panels improves accuracy for risk stratification in prostate cancer management.